Prior to the elucidation of PPARg-mediated anti-inflammatory and cellular protective mechanisms in both the periphery and the CNS, the therapeutic efficacy of PPARg agonists was thought to reside solely in its capacity to significantly increase peripheral insulin sensitivity, protect pancreatic beta cells, and indirectly provide cardioprotection by ameliorating insulin resistance [76]. The gene discussed is INS; the disease is Insulin resistance.